There is still plenty of reason to worry about unproven stem cells being marketed in the U.S. and elsewhere around the world. I’ll start with a new item here in the U.S. on a firm called MD Stem Cells and end with a newly published paper about how things are going in Poland on this […]
Weekly reads: MD Stem Cells, embryo models & headaches, cell therapy trial updates Read More »
I’ve written before about Liz Parrish and her life-extension firm BioViva. Now they appear to have connections with another entity called Integrated Health Systems or IHS, according to a new Wired article. Some of what is going on with IHS and maybe BioViva in Mexico seems extremely risky to me. BioViva, Parrish, and Integrated Health Systems The
Weekly reads: BioViva & life-extension clinic, RMATs, universal cells Read More »
I often get asked about where things stand with stem cell therapy for back pain, which is the focus of today’s post. Back pain is a complex condition with many potential causes. New treatments are needed as existing approaches often don’t work that well. What about stem cells? Stem cell therapy or other cell therapy
Can stem cell therapy for back pain work? Read More »
Occasionally when I write a post there is an angry reaction to it in the blog comments, which was the case for my recent fact-check of the LifeWave X39 patches. As you can see in that post, I didn’t find convincing data to either back up the claimed stem cell connection. In my opinion, there
Weekly reads: bat stem cells & viruses, Lineage Cell, He Jiankui visa Read More »
What is the cell therapy for ALS called NurOwn? How strong is its potential as a treatment for ALS? I’ve been following the biotech BrainStorm Cell Therapeutics for many years. Patients keep asking me about NurOwn ALS prospects. They’re looking for hope. Today’s post is a close look at NurOwn and at BrainStorm as a
Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS? Read More »
Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they
2023 stem cell & regenerative medicine predictions Read More »
Stem cell stroke therapy research has generated buzz over the years. The goal of today’s post is to fact-check claims about supposed stem cell stroke therapies and educate readers on where clinical research stands. There is some real hope here in the long run, but things have been greatly exaggerated at times. Some clinics are
Fact-checking stem cell stroke therapy: hope but not there yet Read More »
Hematopoietic stem cells have many clinical applications and a company called Gamida Cell has an interesting product in this area called Omidubicel that may have several applications. I’m going to start the weekly reads with news there. Gamida Cell and the FDA A recent piece discussed how Omidubicel is progressing with the FDA. FDA extends
Weekly reads: Gamida Cell, Siddhartha Mukherjee, CRISPR in viruses Read More »
A new stem cells for ALS treatment trial represents a big step forward. It’s early days still but this trial shows feasibility and provides a helpful foundation for moving forward. It also highlights challenges. The work is from a team led by Clive Svendsen. Stem cells for ALS treatment trial Here’s the study. Transplantation of
When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are
ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »